Literature DB >> 2971663

Human T-lymphocyte activation is associated with changes in O-glycan biosynthesis.

F Piller1, V Piller, R I Fox, M Fukuda.   

Abstract

The activation of human T-lymphocytes by anti-CD3 antibodies and interleukin-2 results in a marked increase in apparent molecular weight of the major cell-surface sialoglycoprotein. Both forms of the sialoglycoprotein were identified as leukosialin by a monospecific antiserum, and the differences in molecular weight were found to be due to changes in the carbohydrate structures. Our results suggest that resting T-lymphocytes express on leukosialin the disialotetrasaccharides NeuNAc alpha 2----3Gal beta 1----3(NeuNAc alpha 2----6)Gal-NAc-Ser/Thr, whereas activated human T-cells carry on leukosialin exclusively the more complex structures NeuNAc alpha 2----3Gal beta 1----3(NeuNAc alpha 2----3Gal beta 1----4GlcNAc beta 1----6)GalNAc-Ser/Thr. The radical shift in the biosynthetic pathway of O-glycans in activated T-lymphocytes compared to resting cells is apparently caused by a decrease of alpha 2----6 sialyltransferase activity and by the parallel dramatic stimulation of the beta 1----6GlcNAc-transferase. Since both enzymes compete for the same precursor substrate, the coordinate changes in their activities are most likely responsible for the complete change of the carbohydrate structures on leukosialin during the activation of human T-lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971663

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

Review 1.  CD43, a molecule with multiple functions.

Authors:  Y Rosenstein; A Santana; G Pedraza-Alva
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Development of monoclonal antibodies against bovine mucin core 2 beta6 N-acetylglucosaminyltransferase.

Authors:  C M Li; N Joshee; K B Adler; P W Cheng
Journal:  Glycoconj J       Date:  1999-09       Impact factor: 2.916

3.  CD43 gene expression is mediated by a nuclear factor which binds pyrimidine-rich single-stranded DNA.

Authors:  O C Farokhzad; J M Teodoridis; H Park; M A Arnaout; C S Shelley
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

Review 4.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

Review 5.  Qualitative differences between naïve and memory T cells.

Authors:  Marion Berard; David F Tough
Journal:  Immunology       Date:  2002-06       Impact factor: 7.397

Review 6.  T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival.

Authors:  Mary C Clark; Linda G Baum
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

7.  CD43 is relocated from the basal to the apical plasma membrane of rat uterine epithelial cells by progesterone.

Authors:  L Lecce; Y Kaneko; C R Murphy
Journal:  Histochem Cell Biol       Date:  2010-03-24       Impact factor: 4.304

8.  Processing O-glycan core 1, Gal beta 1-3GalNAc alpha-R. Specificities of core 2, UDP-GlcNAc: Gal beta 1-3 GalNAc-R(GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase and CMP-sialic acid: Gal beta 1-3GalNAc-R alpha 3-sialyltransferase.

Authors:  W Kuhns; V Rutz; H Paulsen; K L Matta; M A Baker; M Barner; M Granovsky; I Brockhausen
Journal:  Glycoconj J       Date:  1993-10       Impact factor: 2.916

9.  Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells.

Authors:  Toshie Iwai; Takashi Kudo; Risa Kawamoto; Tomomi Kubota; Akira Togayachi; Toru Hiruma; Tomoko Okada; Toru Kawamoto; Kyoei Morozumi; Hisashi Narimatsu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-08       Impact factor: 11.205

10.  Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome.

Authors:  M Thurnher; S Rusconi; E G Berger
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.